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Abstract
Background: Liver tumour ablation is an operator-dependent procedure. The determination of the opti-
mum needle trajectory and correct ablation parameters could be challenging. The aim of this study was
to report the utility of a new, procedure planning software for microwave ablation (MWA) of liver tumours.
Methods: This was a feasibility study in a pilot group of five patients with nine metastatic liver
tumours who underwent laparoscopic MWA. Pre-operatively, parameters predicting the desired abla-
tion zones were calculated for each tumour. Intra-operatively, this planning strategy was followed for
both antenna placement and energy application. Post-operative 2-week computed tomography (CT)
scans were performed to evaluate complete tumour destruction.
Results: The patients had an average of two tumours (range 1–4), measuring 1.9  0.4 cm (range
0.9–4.4 cm). The ablation time was 7.1  1.3 min (range 2.5–10 min) at 100W. There were no compli-
cations or mortality. The patients were discharged home on post-operative day (POD) 1. At 2-week CT
scans, there were no residual tumours, with a complete ablation demonstrated in all lesions.
Conclusions: This study describes and validates pre-treatment planning software for MWA of liver
tumours. This software was found useful to determine precisely the ablation parameters and needle
placement to create a predicted zone of ablation.
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Introduction
Although liver resection offers patients with malignant liver
tumours the best chance of a cure, the majority of the patients
are not candidates because of inadequate liver remnant, under-
lying cirrhosis and accompanying medical co-morbidities.
Thermal ablation modalities, including radiofrequency ablation
(RFA) and microwave ablation (MWA) offer treatment options
to a significant number of these patients in whom a hepatec-
tomy is not feasible. These ablation modalities are needle-based
therapies that rely on the skill and experience of the surgeon
or radiologist performing the procedure. The success of the
procedure depends on the selection of a correct ablation algo-
rithm, and accurate needle placement, to ensure the creation
of an ablation zone encompassing the tumour with a margin.
Pre-treatment planning, with the pre-operative determina-
tion of the surgical strategy, in regards to how the lesions in a
given patient will be treated, may increase the efficiency and
efficacy of the operation. Furthermore, this may also help in
simplifying the procedure when an ablation modality with a
complex algorithm is utilized.
Microwave thermosphere ablation is a newer technology,
which offers significant advantages when compared with RFA,
in terms of more efficient tissue heating, with potentially
shorter ablation times and fewer treatment failures owing to a
less prominent ‘heat sink effect’.1–8 Although there are reports
on pre-planning for percutaneous RFA under computer
tomography (CT) guidance in the radiology literature,9,10 pre-
planning for a surgical liver tumour ablation is a new concept,
with no reports on MWA. The aim of this study was to
describe the initial clinical use of a new, planning software for
microwave thermosphere ablation of malignant liver tumours.
Patients and methods
This was an Institutional Review Board-approved prospective
study. Pre-treatment planning software (Emprint Procedure
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Planning Application, Covidien, Boulder, CO, USA) was used
to determine the treatment strategy in patients undergoing
laparoscopic MWA of malignant liver tumours. The patients’
tri-phasic CT scans were loaded into the software, and the
lesions were individually selected using target markers around
the tumours in the axial, coronal and sagittal planes. A three-
dimensional image of the lesion was created by the software
(Fig. 1). Using a second set of target markers, the desired zone
of ablation was overlapped around the tumour (Fig. 2). This
projected ablation zone could be moved around the tumour,
and its size in three dimensions could be adjusted using the
computer mouse. Based on the predicted zone of ablation, the
software calculated the ablation diameter, antenna insertion
depth, and minimum and maximum margin covered around
the tumour. By choosing the power setting, the software calcu-
lated the time required to create that ablation zone. Using the
computer mouse, the needle angle, insertion length and its
position within the tumour could be adjusted for the surgeon
to choose the final ablation parameters.
This pre-planning software was used and validated in five
patients who underwent laparoscopic MWA of nine malignant
liver tumours between December 2014 and January 2015, by
one surgeon (E.B.). The tumours were treated by following the
parameters determined by this software pre-operatively. The
microwave probe was inserted under laparoscopic ultrasound
guidance into the tumours at the position determined by the
pre-treatment software, and the ablation was carried out for
the duration of time again calculated by this software pre-
operatively. CT scans, obtained 2 weeks after ablation, were
analysed for completeness of tumour destruction, guided by
the planning software. Continuous data are expressed as the
mean  standard error of the mean.
Surgical procedure
The procedure was done under general endotracheal anaesthe-
sia, with the patients supine. Two grammes of cefazolin was
administered intravenously for antibiotic prophylaxis. Two
12-mm trocars were used in the right upper quadrant, 1 for
the angled laparoscope and the other for the laparoscopic
10 MHz linear, side-viewing ultrasound transducer (Aloka,
Wallingford, CT, USA). Initially diagnostic laparoscopy was
performed, followed by surgeon-performed liver ultrasound. In
those patients without a pre-operative tissue confirmation, a
percutaneous biopsy of a representative lesion was performed
using an automated biopsy gun. The size and the location of
tumours were recorded. Then the microwave ablation antenna
Figure 1 The computer captures are showing pre-treatment planning, which involves the selection of the liver tumour with the region of
interest marker (green circle) in the axial, coronal and sagittal planes. Once this is done, the software creates a three-dimensional image
of the lesion. Then another region of interest (red circle) is placed around the tumour, to represent the ablation zone planned. The
software also demonstrates how the needle needs to be positioned within the tumour to create this ablation zone. This projected
ablation zone can be moved around the tumour, and its size in three dimensions can be adjusted using the computer mouse. The
insertion angle and depth of the needle can also be changed. In the final window, the software displays the predicted ablation zone
overlapping around the tumour, which can be magnified to see the exact position of the antenna
HPB 2015, 17, 632–636 ª 2015 International Hepato-Pancreato-Biliary Association
HPB 633
(a)
(b)
(C)
(D)
Figure 2 The use of the software in a 76-year-old patient with a solitary colorectal metastasis in segment 7 measuring
1.5 9 1.7 9 1.7 cm (a). Initially, target regions of interest are placed around the tumour (green circle). Subsequently, additional targets of
interest are placed around the tumour and the planned zone of ablation is created (red circle). This geometry is then applied intra-
operatively by laparoscopically placing the antenna inside the lesion as precisely as planned (b) and performing microwave ablation
(MWA) at 100 W for 3 min. A post-treatment 2-week computed tomography (CT) scan demonstrates an ablation zone encompassing the
tumour, in the shape, size and position predicted by the software (c–d)
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(Emprint Procedure Planning Application, Covidien) was taken
into the field and introduced to the abdomen through a 3-mm
trocar placed between the ultrasound trocar and the costal
margin. The antenna was then inserted into the liver paren-
chyma parallel to the transducer and positioned within the
tumour based on the details obtained from the pretreatment
planning software. The ablation was then performed based on
the time again that was calculated pre-operatively from the
planning software. The needle was then withdrawn out of the
liver using ‘track ablation’ where 100 W of power was applied
as it was being pulled out. After all the lesions had been
ablated, haemostasis was obtained, and the trocars were
removed. The fascial incisions for the 12-mm trocar sites were
closed with #0 absorbable stitch. This was followed by skin clo-
sure. The patients were discharged home on the next day.
Results
There were four females and one male, with a mean age of
66 years (range 56–76). Three patients had colorectal cancer,
one patient ovarian cancer and another patient leiomyoma
metastases to the liver. The patients had an average of two
tumours (range 1–4), measuring 1.9  0.4 cm (range 0.9–4.4).
The ablation time was 6.4  1.2 min (range 2.5–10) at 100 W.
There were no complications or mortality. The patients were
discharged home on post-operative day (POD) 1. At 2-week
CT scans, there were no residual tumours, with a complete
ablation demonstrated in all lesions. Table 1 summarizes the
details of each lesion treated in the study.
Discussion
This study demonstrates the utility of pre-treatment planning
software to determine the ablation parameters for MWA in a
pilot group of patients with malignant liver tumours. To our
knowledge, this is the first description of planning software for
laparoscopic liver tumour MWA. Overall, the software was
found to be helpful in outlining the details of ablation for
individual tumours before going into the operating room,
thereby facilitating the procedure and not leaving the room for
unexpected intra-operative decision-making. Subjectively, this
increased the efficiency of the procedure. The software was val-
idated by demonstrating complete ablation in all tumours trea-
ted, without any complications.
Nevertheless, there are some drawbacks of the software that
need to be improved. First of all, it does not allow the surgeon to
pick antenna trajectories based on the laparoscopic exposure
expected in a given patient. Second, it does not have augmented
reality built-in to move the liver in three-dimensions, to again
100% simulate a surgical needle placement. Still, its best utility
was recognized as being able to determine ablation parameters
for a given lesion, using the new microwave thermosphere tech-
nology used in the study. The ablation parameters were more
complex compared with RFA and, therefore, the use of this soft-
ware was found to simplify the ablation planning.
Although, the development of this software is a first step in
optimizing ablation parameters, it does not include a needle-
tracking feature or automation regarding needle placement.
Currently, the performance of liver tumour ablation is operator
dependent, with the efficacy of needle placement varying with
experience of the surgeon. As shown in other abdominal surgical
procedures, robotic assistance can improve the precision of
antenna placement. There is ongoing work in automation of this
process for percutaneous ablation with robots used in CT scan-
ner units9; however, developing an automated laparoscopic nee-
dle/antenna placement system for liver tumour ablation involves
more complex tasks, such as being able to provide augmented
reality and adjusting to different needle angles in a given patient,
based on the relationship between the costal margin, liver and
visceral organs. Nevertheless, with the developments in robotic
surgical systems, future advances are possible in this field.
Solomon et al.9 have reported on a percutaneous tumour
ablation planning coupled to robotic needle placement. In the
system described, predicted ablation zones are overlaid on the
CT images of a patient’s tumour. However, these images were
obtained while the patient was on the table for the procedure.
Table 1 The details of individual lesions, ablation parameters and ablation zones obtained at 2-week computed tomography (CT) scans
Lesion Tumour
type
Size (cm) Liver
segment
Proximity to
>4 mm blood
vessel
Location Ablation
power
(W)
Ablation
time
(min)
Predicted
ablation
Diameter (cm)
Ablation Zone
at 2-week CT
(cm)
1 Colorectal 3.2 9 2.8 9 1.7 III Near Superficial 100 10 4 4.8 9 3.5 9 4.4
2 Ovarian 4.4 9 3.9 9 3.5 VIII Near Superficial 100 10 4 3.9 9 4.5 9 3.7
3 Colorectal 0.7 9 0.9 9 0.8 V Near Central 100 2.5 3 2.9 9 2.3 9 2.7
4 Colorectal 1.5 9 0.8 9 1.2 V Near Central 100 10 4 3.8 9 3.8 9 4.1
5 Colorectal 1.6 9 1.4 9 1.3 VII Near Superficial 100 3 3.1 3.2 9 3.4 9 3.4
6 Leiomyosarcoma 1.9 9 1.7 9 1.2 IVb Near Superficial 100 4.5 3.4 3.8 9 3.8 9 3.7
7 Leiomyosarcoma 1.1 9 1.2 9 1.1 VII Away Superficial 100 10 4 3.8 9 4.3 9 4.3
8 Leiomyosarcoma 1.1 9 1.1 9 0.9 II Away Superficial 100 4.5 3.4 3.2 9 3.4 9 3.7
9 Leiomyosarcoma 0.8 9 1.2 9 1.2 IVa Near Central 100 3 3.1 4.0 9 3.7 9 4.2
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The needle is then loaded into a robotic needle holder. When the
accepted coordinates are transferred from the treatment plan-
ning system to the robot, the robot manoeuvers the applicator to
the correct needle trajectory. The authors validated this tech-
nique in two patients, with no evidence of local recurrence at
6 months.
In conclusion, this report describes a novel, pre-treatment
software for MWA planning, whose utility was validated in a
pilot series of surgical patients. Although it has some limitations,
it was found to facilitate the surgical procedures. A prospective
study is being conducted prospectively to further analyse the size
of the ablation zones achieved in comparison to those predicted
by the software, in a larger number of patients.
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